The CGTLive™ Neurology specialty topic page houses video interviews with key opinion leaders in the field of neurology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to cell therapies, gene therapies, and engineered and regenerative medicines developed for neurologic disorders and diseases. It also contains up-to-date clinical news coverage in the field of gene and cell therapy for central nervous system disorders.
March 18th 2024
The gene-edited cell therapy has been approved as Lenmeldy by the FDA.
Open-Label Studies Are Insufficient to Establish the Potential of CAR-T in Autoimmune Disease
March 13th 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed the need for randomized-control trials for CAR-T in lupus and other autoimmune diseases.
Paul Melmeyer, MPP, on Advocacy and Progress in Rare Neuromuscular Diseases From a Policy Standpoint
February 29th 2024In observance of Rare Disease Day 2024, the vice president of public policy and advocacy at the Muscular Dystrophy Association discussed advocacy and policy progress regarding rare neuromuscular diseases.
Long-Term Effects of CAR-T on Children’s Brains Remain Largely Unknown and More Research is Needed
February 26th 2024Juliane Gust, MD, PhD, an assistant professor of neurology at University of Washington, Seattle Children's, discussed a study that is currently underway via the NIH’s CARnation Consortium that will seek to address this gap in knowledge.
Juliane Gust, MD, PhD, on Evaluating Longterm Neurological Outcomes for CAR-T in Pediatric Patients
February 21st 2024The assistant professor of neurology at University of Washington, Seattle Children's discussed efforts to address a gap in knowledge in the long-term effects of CAR-T, if any, on children’s neurological development.